Surgical removal of parts of the liver remains the only curative approach for patients with liver-specific cancer.
FDA breakthrough device decisions rebound after recent declines
The Food and Drug Administration designated 166 products under its breakthrough devices program in its most recent financial year, reversing the downward trend seen as
November 14, 2024